IFNB1 and relapsing-remitting multiple sclerosis: With the aim to increase efficiency and to reduce side effects of IFNβ therapy, tremendous efforts have been undertaken to understand IFNβ–mediated actions in the pathogenesis of RRMS and have also been studied in the murine model, experimental autoimmune encephalomyelitis (EAE) [48].